Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

EU Commission says talking to four companies on COVID vaccine

10/29/2020 | 04:39pm EST

BRUSSELS, Oct 29 (Reuters) - The European Commission is in talks with four companies to secure a potential COVID-19 vaccine, President Ursula von der Leyen said on Thursday following an EU leaders' video conference.

The EU has already secured potential vaccines being developed by AstraZeneca, Sanofi and Johnson & Johnson. It has also said to be in talks with Moderna, CureVac and a partnership of Pfizer and BionTech. (Reporting by Brussels newsroom)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.59% 7840.77174 Delayed Quote.1.60%
MODERNA, INC. 9.97% 157.26 Delayed Quote.705.88%
PFIZER, INC. -1.74% 40.09 Delayed Quote.8.00%
SANOFI 0.66% 83.57 Real-time Quote.-7.35%
All news about ASTRAZENECA PLC
07:31aAfter blazing energy rally, investors check the fuel gauge
RE
02:27aASTRAZENECA : JP Morgan keeps its Buy rating
MD
01:01aFortune or foresight? AstraZeneca and Oxford's stories clash on COVID-19 vacc..
RE
12/03REUTERS SUMMIT-India's economy on the rebound, government focuses on spending..
RE
12/03Canada could approve Pfizer's COVID-19 vaccine within the next week -official..
RE
12/03India's economy on the rebound, government focuses on spending - finance mini..
RE
12/03REUTERS SUMMIT-India's economy on the rebound, government focuses on spending..
RE
12/03ASTRAZENECA : Fortune or foresight? AstraZeneca and Oxford's stories clash on CO..
RE
12/03U.K.'s Covid-19 Vaccine Program to Test Its State-Run Medical System
DJ
12/03Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
RE
More news
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 978 M - -
Net Debt 2020 13 237 M - -
P/E ratio 2020 44,0x
Yield 2020 2,71%
Capitalization 136 B 137 B -
EV / Sales 2020 5,65x
EV / Sales 2021 4,91x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 122,43 $
Last Close Price 103,98 $
Spread / Highest target 54,0%
Spread / Average Target 17,7%
Spread / Lowest Target -36,5%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC1.60%136 826
JOHNSON & JOHNSON2.15%392 249
ROCHE HOLDING AG-4.55%287 762
PFIZER, INC.8.00%222 836
NOVARTIS AG-11.95%206 585
MERCK & CO., INC.-10.45%206 071